Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Cancers (Basel) ; 13(11)2021 Jun 02.
Article in English | MEDLINE | ID: mdl-34199386

ABSTRACT

To adopt prevention strategies in gastric cancer, it is imperative to develop robust biomarkers with acceptable costs and feasibility in clinical practice to stratified populations according to risk scores. With this aim, we applied an unbiased genome-wide CpG methylation approach to a discovery cohort composed of gastric cancer (n = 24), and non-malignant precursor lesions (n = 64). Then, candidate-methylation approaches were performed in a validation cohort of precursor lesions obtained from an observational longitudinal study (n = 264), with a 12-year follow-up to identify repression or progression cases. H. pylori stratification and histology were considered to determine their influence on the methylation dynamics. As a result, we ascertained that intestinal metaplasia partially recapitulates patterns of aberrant methylation of intestinal type of gastric cancer, independently of the H. pylori status. Two epigenetically regulated genes in cancer, RPRM and ZNF793, consistently showed increased methylation in intestinal metaplasia with respect to earlier precursor lesions. In summary, our result supports the need to investigate the practical utilities of the quantification of DNA methylation in candidate genes as a marker for disease progression. In addition, the H. pylori-dependent methylation in intestinal metaplasia suggests that pharmacological treatments aimed at H. pylori eradication in the late stages of precursor lesions do not prevent epigenome reprogramming toward a cancer signature.

2.
Gastroenterol Hepatol ; 44(6): 448-464, 2021.
Article in English, Spanish | MEDLINE | ID: mdl-33609597

ABSTRACT

This position paper, sponsored by the Asociación Española de Gastroenterología [Spanish Association of Gastroenterology], the Sociedad Española de Endoscopia Digestiva [Spanish Gastrointestinal Endoscopy Society] and the Sociedad Española de Anatomía Patológica [Spanish Anatomical Pathology Society], aims to establish recommendations for performing an high quality upper gastrointestinal endoscopy for the screening of gastric cancer precursor lesions (GCPL) in low-incidence populations, such as the Spanish population. To establish the quality of the evidence and the levels of recommendation, we used the methodology based on the GRADE system (Grading of Recommendations Assessment, Development and Evaluation). We obtained a consensus among experts using a Delphi method. The document evaluates different measures to improve the quality of upper gastrointestinal endoscopy in this setting and makes recommendations on how to evaluate and treat the identified lesions. We recommend that upper gastrointestinal endoscopy for surveillance of GCPL should be performed by endoscopists with adequate training, administering oral premedication and use of sedation. To improve the identification of GCPL, we recommend the use of high definition endoscopes and conventional or digital chromoendoscopy and, for biopsies, NBI should be used to target the most suspicious areas of intestinal metaplasia. Regarding the evaluation of visible lesions, the risk of submucosal invasion should be evaluated with magnifying endoscopes and endoscopic ultrasound should be reserved for those with suspected deep invasion. In lesions amenable to endoscopic resection, submucosal endoscopic dissection is considered the technique of choice.


Subject(s)
Consensus , Endoscopy, Gastrointestinal/standards , Precancerous Conditions/diagnostic imaging , Stomach Neoplasms/diagnostic imaging , Anesthesia , Delphi Technique , Endoscopy, Gastrointestinal/methods , Humans , Premedication , Societies, Medical , Spain
3.
Gastroenterol. hepatol. (Ed. impr.) ; 44(1): 67-86, ene. 2021. tab, graf
Article in Spanish | IBECS | ID: ibc-202203

ABSTRACT

Este documento de posicionamiento, auspiciado por la Asociación Española de Gastroenterología, la Sociedad Española de Endoscopia Digestiva y la Sociedad Española de Anatomía Patológica, tiene como objetivo establecer recomendaciones para el cribado del cáncer gástrico (CG) en poblaciones con incidencia baja, como la española. Para establecer la calidad de la evidencia y los niveles de recomendación se ha utilizado la metodología basada en el sistema GRADE (Grading of Recommendations Assessment, Development and Evaluation). Se obtuvo el consenso entre expertos mediante un método Delphi. El documento evalúa el cribado en población general, individuos con familiares con CG y lesiones precursoras de CG (LPCG). El objetivo de las intervenciones debe ser la reducción de la mortalidad por CG. Se recomienda el uso de la clasificación OLGIM y determinar el subtipo de metaplasia intestinal (MI) para evaluar las LPCG. No se recomienda establecer cribado poblacional endoscópico de CG ni de Helicobacter pylori. Sin embargo, el documento establece una recomendación fuerte para el tratamiento de H.pylori si se detecta la infección, y su investigación y tratamiento en individuos con antecedentes familiares de CG o con LPCG. En cambio, no se recomienda el uso de test serológicos para detectar LPCG. Se sugiere cribado endoscópico únicamente en los individuos con criterios de CG familiar. En cuanto a los individuos con LPCG, solo se sugiere vigilancia endoscópica ante MI extensa asociada a algún factor de riesgo adicional (MI incompleta y/o antecedentes familiares de CG) tras la resección de lesiones displásicas o en pacientes con displasia sin lesión visible tras una endoscopia digestiva alta de calidad con cromoendoscopia


This positioning document, sponsored by the Asociación Española de Gastroenterología, the Sociedad Española de Endoscopia Digestiva and the Sociedad Española de Anatomía Patológica, aims to establish recommendations for the screening of gastric cancer (GC) in low incidence populations, such as the Spanish. To establish the quality of the evidence and the levels of recommendation, we used the methodology based on the GRADE system (Grading of Recommendations Assessment, Development and Evaluation). We obtained a consensus among experts using a Delphi method. The document evaluates screening in the general population, individuals with relatives with GC and subjects with GC precursor lesions (GCPL). The goal of the interventions should be to reduce GC related mortality. We recommend the use of the OLGIM classification and determine the intestinal metaplasia (IM) subtype in the evaluation of GCPL. We do not recommend to establish endoscopic mass screening for GC or Helicobacter pylori. However, the document strongly recommends to treat H.pylori if the infection is detected, and the investigation and treatment in individuals with a family history of GC or with GCPL. Instead, we recommend against the use of serological tests to detect GCPL. Endoscopic screening is suggested only in individuals that meet familial GC criteria. As for individuals with GCPL, endoscopic surveillance is only suggested in extensive IM associated with additional risk factors (incomplete IM and/or a family history of GC), after resection of dysplastic lesions or in patients with dysplasia without visible lesion after a high quality gastroscopy with chromoendoscopy


Subject(s)
Humans , Stomach Neoplasms/diagnosis , Early Detection of Cancer/methods , Carcinogenesis/pathology , Mass Screening/methods , Helicobacter pylori/isolation & purification , Helicobacter Infections/epidemiology , Gastritis/epidemiology , Metaplasia/pathology
4.
Gastroenterol Hepatol ; 44(1): 67-86, 2021 Jan.
Article in English, Spanish | MEDLINE | ID: mdl-33252332

ABSTRACT

This positioning document, sponsored by the Asociación Española de Gastroenterología, the Sociedad Española de Endoscopia Digestiva and the Sociedad Española de Anatomía Patológica, aims to establish recommendations for the screening of gastric cancer (GC) in low incidence populations, such as the Spanish. To establish the quality of the evidence and the levels of recommendation, we used the methodology based on the GRADE system (Grading of Recommendations Assessment, Development and Evaluation). We obtained a consensus among experts using a Delphi method. The document evaluates screening in the general population, individuals with relatives with GC and subjects with GC precursor lesions (GCPL). The goal of the interventions should be to reduce GC related mortality. We recommend the use of the OLGIM classification and determine the intestinal metaplasia (IM) subtype in the evaluation of GCPL. We do not recommend to establish endoscopic mass screening for GC or Helicobacter pylori. However, the document strongly recommends to treat H.pylori if the infection is detected, and the investigation and treatment in individuals with a family history of GC or with GCPL. Instead, we recommend against the use of serological tests to detect GCPL. Endoscopic screening is suggested only in individuals that meet familial GC criteria. As for individuals with GCPL, endoscopic surveillance is only suggested in extensive IM associated with additional risk factors (incomplete IM and/or a family history of GC), after resection of dysplastic lesions or in patients with dysplasia without visible lesion after a high quality gastroscopy with chromoendoscopy.


Subject(s)
Consensus , Mass Screening/methods , Stomach Neoplasms/diagnosis , Carcinoma in Situ/diagnosis , Carcinoma in Situ/surgery , Delphi Technique , Family Health , Gastroscopy , Helicobacter Infections/diagnosis , Helicobacter Infections/drug therapy , Humans , Incidence , Intestines/pathology , Metaplasia/diagnosis , Metaplasia/pathology , Precancerous Conditions/diagnosis , Societies, Medical , Spain , Stomach Neoplasms/epidemiology , Stomach Neoplasms/therapy
5.
Biom J ; 63(3): 632-649, 2021 03.
Article in English | MEDLINE | ID: mdl-33345346

ABSTRACT

We present a novel approach for analysing multivariate case-control georeferenced data in a Bayesian disease mapping context using stochastic partial differential equations (SPDEs) and the integrated nested Laplace approximation (INLA) for model fitting. In particular, we propose smooth terms based on SPDE models to estimate the underlying spatial variation as well as risk associated to pollution sources. Log-Gaussian Cox processes are used to estimate the intensity of the cases and controls, to account for risk factors and include a term to measure spatial residual variation. Each intensity is modelled on a baseline spatial effect (estimated from both controls and cases), a disease-specific spatial term and the effects of some covariates. By fitting these models, the residual spatial terms can be easily compared to detect high-risk areas not explained by the covariates. Three different types of effects to model exposure to pollution sources are considered on the distance to the source: a fixed effect, a smooth term to model non-linear effects by means of a discrete random walk of order one and a Gaussian process in one dimension with a Matérn covariance function. Spatial terms are modelled using a Gaussian process in two dimensions with a Matérn covariance function and are approximated using an approach based on solving an SPDE through INLA. Finally, this new framework is applied to a dataset of three different types of cancer and a set of controls from Alcalá de Henares (Madrid, Spain). Covariates available include the distance to several polluting industries and socioeconomic indicators. Our findings point to a possible risk increase due to the proximity to some of these industries.


Subject(s)
Neoplasms , Bayes Theorem , Humans , Multivariate Analysis , Risk Factors , Spain
6.
Cancer Epidemiol ; 68: 101791, 2020 10.
Article in English | MEDLINE | ID: mdl-32823056

ABSTRACT

BACKGROUND: Peru has a public health problem because of asbestos imports. We analyzed the mortality trends for mesothelioma in Peru and its provinces from 2005 to 2014 and estimated their relationship with the amount of asbestos imported previously. METHODS: We computed age-standardized mortality rates (ASMRs) per 100,000 population (direct method and SEGI world standard population reference), and the standardized mortality ratio (SMR). The relationship between the amount of asbestos imported annually along the period 1965-2010 and the number of mesothelioma deaths per year from 2005 to 2014 was estimated by log-linear Poisson regression models and Pearson correlation calculations. RESULTS: After correcting the number of deaths, Peru registered 428 cases (or 430 when corrected cases are rounded by sex) between 2005 and 2014. The highest ASMRs were in Arequipa and Callao (range: 0.40-0.41/100,000 population), followed by Huancavelica (0.36/100,000 population). This translates into approximately one death per each 68-111 of asbestos tons imported. The latency period for the higher level of positive correlation found was 8 years (r = 0.8). Male female sex ratio was lower in provinces such as Junin and Hunacavelica with geological asbestos risk. CONCLUSIONS: Two patterns of mesothelioma risk have been detected, occupational and environmental. During the 2002-2006 years, Peru increased the asbestos use. If crocidolite imports were also increased, this could be behind the 8 years latency period detected. Peru should boost strategies towards the total ban of all forms of asbestos.


Subject(s)
Asbestos/adverse effects , Carcinogens/toxicity , Mesothelioma/mortality , Occupational Exposure/adverse effects , Adolescent , Adult , Child , Child, Preschool , Female , Geography , Humans , Infant , Infant, Newborn , Male , Mesothelioma/epidemiology , Mesothelioma/etiology , Middle Aged , Peru/epidemiology , Prognosis , Survival Rate , Young Adult
7.
Int J Cancer ; 143(11): 2777-2786, 2018 12 01.
Article in English | MEDLINE | ID: mdl-30171605

ABSTRACT

Gastric carcinogenesis proceeds through a series of gastric cancer precursor lesions (GCPLs) leading to gastric cancer (GC) development. Although Helicobacter pylori infection initiates this process, genetic factors also play a role. We previously reported that genetic variability in MUC2 is associated with the evolution of GCPLs. In order to replicate previous results in an independent sample series and to explore whether genetic variability in other candidate genes plays a role in the evolution of GCPL, genomic DNA from 559 patients with GCPLs, recruited from 9 Spanish hospitals and followed for a mean of 12 years, was genotyped for 141 SNPs in 29 genes. After follow-up, 45.5% of the lesions remained stable, 37% regressed and 17.5% progressed to a more severe lesion. Genetic association with the evolution of the lesions (progression or regression) was analyzed by multinomial and binomial logistic regression. After correction for multiple comparisons, the results obtained confirmed the inverse association between MUC2 variants and the regression of the lesions. A significant association was also observed between NFKB1 and CD14 variants and the evolution of the lesions; interestingly, this association was with both progression and regression in the same direction, which could reflect the dual role of inflammation in cancer. Stratified analyses according to H. pylori virulence factors indicated some significant and differential effects but none of them passed the FDR test. These results confirm that genetic variability in MUC2, NFKB1 and CD14 may have a role in the evolution of the GCPLs along time and in gastric carcinogenesis.


Subject(s)
Genetic Predisposition to Disease/genetics , Lipopolysaccharide Receptors/genetics , Mucin-2/genetics , NF-kappa B p50 Subunit/genetics , Polymorphism, Single Nucleotide/genetics , Precancerous Conditions/genetics , Stomach Neoplasms/genetics , Adult , Aged , Disease Progression , Follow-Up Studies , Genotype , Helicobacter Infections/genetics , Helicobacter pylori/pathogenicity , Humans , Longitudinal Studies , Middle Aged , Precancerous Conditions/pathology , Stomach Neoplasms/pathology
8.
Geospat Health ; 13(1): 616, 2018 05 07.
Article in English | MEDLINE | ID: mdl-29772880

ABSTRACT

The feasibility of the Minimum Basic Data Set (MBDS) as a tool in cancer research was explored monitoring its incidence through the detection of spatial clusters. Case-control studies based on MBDS and marked point process were carried out with the focus on the residence of patients from the Prince of Asturias University Hospital in Alcalá de Henares (Madrid, Spain). Patients older than 39 years with diagnoses of stomach, colorectal, lung, breast, prostate, bladder and kidney cancer, melanoma and haematological tumours were selected. Geocoding of the residence address of the cases was done by locating them in the continuous population roll provided by the Madrid Statistical Institute and extracting the coordinates. The geocoded control group was a random sample of 10 controls per case matched by frequency of age and sex. To assess case clusters, differences in Ripley K functions between cases and controls were calculated. The spatial location of clusters was explored by investigating spatial intensity and its ratio between cases and controls. Results suggest the existence of an aggregation of cancers with a common risk factor such as tobacco smoking (lung, bladder and kidney cancers). These clusters were located in an urban area with high socioeconomic deprivation. The feasibility of designing and carrying out case-control studies from the MBDS is shown and we conclude that MBDS can be a useful epidemiological tool for cancer surveillance and identification of risk factors through case-control spatial point process studies.


Subject(s)
Community Health Centers , Datasets as Topic , Neoplasms/epidemiology , Spatial Analysis , Adult , Databases, Factual , Feasibility Studies , Humans , Neoplasms/classification , Registries , Spain/epidemiology
9.
PLoS One ; 12(4): e0176043, 2017.
Article in English | MEDLINE | ID: mdl-28441455

ABSTRACT

BACKGROUND: Intestinal metaplasia (IM) is a precursor lesion that precedes gastric cancer (GC). There are two IM histological subtypes, complete (CIM) and incomplete (IIM), the latter having higher progression rates to GC. This study was aimed at analysing gene expression and molecular processes involved in the progression from normal mucosa to IM, and also from IM subtypes to GC. METHODOLOGY: We used expression data to compare the transcriptome of healthy gastric mucosa to that of IM not progressing to GC, and the transcriptome of IM subtypes that had progressed to GC to those that did not progress. Some deregulated genes were validated and pathway analyses were performed. RESULTS: Comparison of IM subtypes that had progressed to GC with those that did not progress showed smaller differences in the expression profiles than the comparison of IM that did not progress with healthy mucosa. New transcripts identified in IM not progressing to GC included TRIM, TMEM, homeobox and transporter genes and SNORD116. Comparison to normal mucosa identified non tumoral Warburg effect and melatonin degradation as previously unreported processes involved in IM. Overexpressed antigen processing is common to both IM-subtypes progressing to GC, but IIM showed more over-expressed oncogenic genes and molecular processes than CIM. CONCLUSIONS: There are greater differences in gene expression and molecular processes involved in the progression from normal healthy mucosa to IM than from IM to gastric cancer. While antigen processing is common in both IM-subtypes progressing to GC, more oncogenic processes are observed in the progression of IIM.


Subject(s)
Gastric Mucosa/pathology , Gene Expression Regulation, Neoplastic , Intestines/pathology , Precancerous Conditions/genetics , Stomach Neoplasms/genetics , Disease Progression , Humans , Metaplasia/genetics , Metaplasia/pathology , Precancerous Conditions/pathology , Stomach Neoplasms/pathology , Transcriptome
10.
J Gastroenterol ; 52(1): 39-49, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27032393

ABSTRACT

BACKGROUND: Intestinal metaplasia (IM) is a gastric cancer precursor lesion (GCPL) and an extremely high risk factor for progression to gastric cancer (GC). Clinical guidelines recommend that patients with extensive IM undergo a gastroscopy every 3 years. However, protein biomarkers that indicate a transition from IM to GC are lacking. Our group recently identified an interferon-alpha (IFNα)-responsive gene, Schlafen 4 (Slfn4), in immune cells that correlates with metaplastic changes in Helicobacter-infected mice. We therefore tested the hypothesis that a human homolog of Slfn4, namely, Schlafen 5 (SLFN5), correlates with progression of GCPL to GC. METHODS: Jurkat T-lymphoid and HL-60 myeloid cell lines were treated with IFNα, and SLFN5 mRNA was quantified by quantitative PCR. SLFN5 protein expression in the inflamed gastric mucosa was co-localized to specific immune cell types by immunohistochemistry using CD20, CD2, and MAC2 antibodies. SLFN5 expression was also determined by immunohistochemistry in formalin-fixed paraffin-embedded samples from individuals with non-atrophic gastritis, atrophic gastritis, complete IM, incomplete IM, and GC, respectively. RESULTS: The IFNα treatment of Jurkat and HL-60 cells induced SLFN5 mRNA. SLFN5 protein was expressed mainly by T lymphocytes in inflamed gastric mucosa. The highest level of SLFN5 expression was observed in patients with IM that progressed to GC. Receiver operating characteristic curves demonstrated that correlating SLFN5 expression with the histologic diagnosis of IM significantly increased the probability of identifying patients who may progress to GC. CONCLUSION: In this study population, elevated SLFN5 protein expression in patients with IM correlated with progression to GC.


Subject(s)
Cell Cycle Proteins/genetics , Interferon-alpha/administration & dosage , Intestines/pathology , Stomach Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Disease Progression , Female , Gastric Mucosa/pathology , Gene Expression Regulation, Neoplastic , HL-60 Cells , Humans , Immunohistochemistry , Jurkat Cells , Male , Metaplasia , Middle Aged , RNA, Messenger/metabolism , Stomach Neoplasms/genetics , T-Lymphocytes/metabolism , Young Adult
11.
Eur J Intern Med ; 34: 94-97, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27499180

ABSTRACT

OBJECTIVE: This work aims to evaluate the Minimum Basic Data Set (MBDS) as a data source in the detection of malignant tumors and explore its usefulness as a tool for epidemiological surveillance of cancer. MATERIALS AND METHODS: MBDS hospital data discharge from Prince of Asturias University Hospital (HUPA, Alcalá de Henares, Madrid, Spain) and cancer cases recorded in the Hospital Cancer Registry (HCR) have been collected for the period between January 2012 and June 2014. Both databases have been linked by the number of clinical history. For the process of evaluation of MBDS, the types of cancer with more than 100 cases have been analyzed and sensitivity, specificity, positive and negative predictive values(PPV, NPV) of MBDS were calculated using as reference the diagnoses recorded in the HCR. RESULTS: 3438 cases of cancer were accounted in the MBDS and 2445 in the HCR. The MBDS has a sensitivity to detect cases of cancer above 60%, although it varies depending on the type of tumor, reaching the highest values for bladder cancer. The specificity and the VPN were very high for all types of cancer studied, always on top of 95%. Finally, the VPP is generally moderate, between 50% and 70%. CONCLUSIONS: The systematic exploitation of the MBDS can provide a valuable tool in the monitoring of cancer by its acceptable sensitivity and high specificity, allowing obtaining information without the delays involved in the consolidation of the annotations of the HCR. Furthermore, its use could partly mitigate the lack of data in important regions of Spain.


Subject(s)
Databases, Factual/standards , Epidemiological Monitoring , Neoplasms/epidemiology , Datasets as Topic , Hospitals , Humans , Sensitivity and Specificity , Spain/epidemiology
12.
J Gastroenterol Hepatol ; 31(5): 953-8, 2016 May.
Article in English | MEDLINE | ID: mdl-26630310

ABSTRACT

BACKGROUND AND AIM: In high or moderate risk populations, periodic surveillance of patients at risk of progression from gastric precursor lesions (PL) to gastric cancer (GC) is the most effective strategy for reducing the burden of GC. Incomplete type of intestinal metaplasia (IIM) may be considered as the best candidate, but it is still controversial and more research is needed. To further assess the progression of subtypes of IM as predictors of GC occurrence. METHODS: A follow-up study was carried-out including 649 patients, diagnosed with PL between 1995-2004 in 9 participating hospitals from Spain, and who repeated the biopsy during 2011-2013. Medical information and habits were collected through a questionnaire. Based on morphology, IM was sub-classified as complete (small intestinal type, CIM) and incomplete (colonic type, IIM). Analyses were done using Cox (HR) models. RESULTS: At baseline, 24% of patients had atrophic gastritis, 38% CIM, 34% IIM, and 4% dysplasia. Mean follow-up was 12 years. 24 patients (3.7%) developed a gastric adenocarcinoma during follow-up. The incidence rate of GC was 2.76 and 5.76 per 1,000 person-years for those with CIM and IIM, respectively. The HR of progression to CG was 2.75 (95% CI 1.06-6.26) for those with IIM compared with those with CIM at baseline, after adjusting for sex, age, smoking, family history of GC and use of NSAIDs. CONCLUSIONS: IIM is the PL with highest risk to progress to GC. Sub-typing of IM is a valid procedure for the identification of high risk patients that require more intensive surveillance.


Subject(s)
Adenocarcinoma/pathology , Cell Transformation, Neoplastic/pathology , Gastritis, Atrophic/pathology , Precancerous Conditions/pathology , Stomach Neoplasms/pathology , Stomach/pathology , Adenocarcinoma/epidemiology , Adult , Biopsy , Disease Progression , Female , Follow-Up Studies , Gastritis, Atrophic/epidemiology , Humans , Longitudinal Studies , Male , Metaplasia , Middle Aged , Multivariate Analysis , Precancerous Conditions/epidemiology , Proportional Hazards Models , Risk Assessment , Risk Factors , Spain/epidemiology , Stomach Neoplasms/epidemiology , Surveys and Questionnaires , Time Factors
13.
EMBO J ; 34(14): 1859-74, 2015 Jul 14.
Article in English | MEDLINE | ID: mdl-25916825

ABSTRACT

Gyrencephalic species develop folds in the cerebral cortex in a stereotypic manner, but the genetic mechanisms underlying this patterning process are unknown. We present a large-scale transcriptomic analysis of individual germinal layers in the developing cortex of the gyrencephalic ferret, comparing between regions prospective of fold and fissure. We find unique transcriptional signatures in each germinal compartment, where thousands of genes are differentially expressed between regions, including ~80% of genes mutated in human cortical malformations. These regional differences emerge from the existence of discrete domains of gene expression, which occur at multiple locations across the developing cortex of ferret and human, but not the lissencephalic mouse. Complex expression patterns emerge late during development and map the eventual location of folds or fissures. Protomaps of gene expression within germinal layers may contribute to define cortical folds or functional areas, but our findings demonstrate that they distinguish the development of gyrencephalic cortices.


Subject(s)
Brain/embryology , Cerebral Cortex/anatomy & histology , Cerebral Cortex/physiology , Ferrets/genetics , Gene Expression Regulation, Developmental , Malformations of Cortical Development/genetics , Animals , Animals, Newborn , Cerebral Cortex/abnormalities , Cerebral Cortex/embryology , Cyclin-Dependent Kinase 6/genetics , Female , Ferrets/embryology , Ferrets/growth & development , Humans , Oligonucleotide Array Sequence Analysis , Organ Size , Pregnancy , Receptor, Fibroblast Growth Factor, Type 2/genetics , Receptor, Fibroblast Growth Factor, Type 3/genetics
14.
Carcinogenesis ; 33(5): 1072-80, 2012 May.
Article in English | MEDLINE | ID: mdl-22402132

ABSTRACT

In order to assess whether inherited genetic variability in the mucin genes associates with the evolution of gastric cancer precursor lesions (GCPLs), we genotyped 22 tagSNPs in MUC1, MUC6 and MUC2 genes of 387 patients with GCPLs that had been followed up for 12.8 years. According to the diagnosis at recruitment and at the end of follow-up, the lesions did not change in 43.1% of the patients, regressed in 28.7% and progressed in 28.2%. Three SNPs in the 3'-moiety of MUC2 were significantly associated with a decreased risk of progression of the lesions, whereas another four SNPs, located at the 5'-moiety, were found to be significantly associated either with increased [one single-nucleotide polymorphism (SNP)] or decreased (three SNPs) probability of regression. Stratified analysis indicated that significance was maintained only in those subjects positive for Helicobacter pylori infection and in those not consuming non-steroidal anti-inflammatory drugs, which were found protective against lesion progression. Haplotype analyses indicated the presence of two haplotypes, one in each moiety of the gene, that were significantly associated with decreased risk of progression of the lesions [odds ratio (OR) = 0.49 and 0.46; 95% confidence interval (CI) = 0.28-0.85 and 0.25-0.86, respectively]. The 5'-end haplotype was also associated with increased probability of regression (OR = 1.67; 95% CI = 1.02-2.73), altogether suggesting a protective role against progression of the precancerous lesions. No significant association was found with variants in MUC1 and MUC6 genes. These results indicate, for the first time, that genetic variability in MUC2 is associated with evolution of GCPLs, especially in H.pylori infected patients, suggesting a role of this secreted mucin in gastric carcinogenesis.


Subject(s)
Mucins/genetics , Precancerous Conditions/genetics , Precancerous Conditions/pathology , Stomach Neoplasms/genetics , Stomach Neoplasms/pathology , Adult , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Disease Progression , Female , Follow-Up Studies , Genetic Predisposition to Disease , Haplotypes , Helicobacter Infections/genetics , Helicobacter Infections/pathology , Helicobacter pylori/isolation & purification , Humans , Male , Middle Aged , Odds Ratio , Polymorphism, Single Nucleotide , Precancerous Conditions/microbiology , Spain , Stomach Neoplasms/drug therapy , Stomach Neoplasms/microbiology
15.
Int J Cancer ; 127(11): 2654-60, 2010 Dec 01.
Article in English | MEDLINE | ID: mdl-20178099

ABSTRACT

There are no established criteria to classify patients into high or low risk of progressing to gastric cancer (GC). The aim of the study was to identify predictors of GC occurrence among patients with gastric preneoplastic lesions. A prospective and retrospective follow-up study was carried out in a province in Spain with one of the highest risk of GC. The study included 478 patients who underwent gastric biopsy in 1988-1994 with diagnoses of normal mucosa, nonatrophic gastritis (NAG), non-metaplastic multifocal atrophic gastritis (MAG) and complete or incomplete intestinal metaplasia (IM) and who accepted to undergo a new biopsy during 2005-2007 or had an event during follow up. Inter- and intra-observer variability of histological diagnosis was assessed. Analysis was done using Cox proportional hazards risk (HR) models. The mean age of the patients was 50 years, 47% were males and the mean follow-up time was 12.8 years. During follow-up, 23 GC (4.8%) were diagnosed (21 adenocarcinomas and 2 lymphomas) with an incidence of 3.77 per 1,000 person per year. The incidence rate of GC for those with incomplete IM was 16.5 per 1,000 person years. Out the 21 adenocarcinomas, 16 had an incomplete IM in the baseline diagnosis. Incomplete IM (HR 11.3; 95% CI 3.8-33.9) and a family history of GC (HR 6.1; 95% CI 1.7-22.4) were the strongest risk factors for gastric adenocarcinoma. Subtyping of IM and family history of GC may be useful for the identification of high-risk patients who need more intensive surveillance.


Subject(s)
Precancerous Conditions/epidemiology , Stomach Neoplasms/epidemiology , Adenocarcinoma/epidemiology , Adenocarcinoma/pathology , Adult , Aged , Disease Progression , Female , Follow-Up Studies , Humans , Incidence , Male , Middle Aged , Precancerous Conditions/pathology , Proportional Hazards Models , Prospective Studies , Retrospective Studies , Risk Factors , Spain/epidemiology , Stomach Neoplasms/mortality , Stomach Neoplasms/pathology
16.
Acta Neuropathol ; 113(6): 637-51, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17294199

ABSTRACT

Cortical cholinergic dysfunction has been correlated with the expression and processing of beta-amyloid precursor protein. However, it remains unclear as to how cholinergic dysfunction and beta-amyloid (Abeta) formation and deposition might be related to one another. Since the M1- and M2 subtypes of muscarinic acetylcholine receptors (mAChRs) are considered key molecules that transduce the cholinergic message, the purpose of the present study was to assess the effects of the injected Abeta peptide on the number of M1mAchR- and M2mAChR-immunoreactive cells in the medial septum-diagonal band (MS-nDBB) complex of the rat. Injections of Abeta protein into the retrosplenial cortex resulted in a decrease in M1mAChR and M2mAChR immunoreactivity in the MS-nDBB complex. Quantitative analysis revealed a significant reduction in the number of M1mAChR- and M2mAChR-immunoreactive cells in the medial septum nucleus (MS) and in the horizontal nucleus of the diagonal band of Broca (HDB) as compared to the corresponding hemisphere in control animals and with that seen in the contralateral hemisphere, which corresponds to the PBS-injected side. Co-localization studies showed that the M1mAChR protein is localized in GABA-immunoreactive cells of the MS-nDBB complex, in particular those of the MS nucleus, while M2mAChR protein is localized in both the cholinergic and GABAergic cells. Moreover, GABAergic cells containing M2mAChR are mainly localized in the MS nucleus, while cholinergic cells containing M2mAChR are localized in the MS and the HDB nuclei. Our findings suggest that Abeta induces a reduction in M1mAChR- and M2mAChR-containing cells, which may contribute to impairments of cholinergic and GABAergic transmission in the MS-nDBB complex.


Subject(s)
Amyloid beta-Peptides/pharmacology , Calcium-Binding Proteins/metabolism , Diagonal Band of Broca/metabolism , Parasympathetic Nervous System/physiology , Receptor, Muscarinic M1/drug effects , Receptor, Muscarinic M2/drug effects , Septum of Brain/metabolism , gamma-Aminobutyric Acid/physiology , Amyloid beta-Peptides/isolation & purification , Animals , Cell Count , Diagonal Band of Broca/drug effects , Female , Immunohistochemistry , Parasympathetic Nervous System/drug effects , Peptide Fragments/isolation & purification , Peptide Fragments/pharmacology , Rats , Rats, Wistar , Septum of Brain/drug effects , Tissue Fixation
SELECTION OF CITATIONS
SEARCH DETAIL
...